Scribe Therapeutics Projected to Enter the Clinic in Mid-2026 with STX-1150, a PCSK9-targeting CRISPR Epigenetic Silencing Therapy for Durable LDL-C Reduction

• Scribe expects to initiate a first-in-human hypercholesterolemia study in mid-2026 with STX-1150, its lead cardiometabolic asset
• STX-1150 is designed to deliver durable therapeutic LDL-C lowering with reduced dosing burden, enabled by epigenetic silencing that does not permanently modify the DNA
• Preclinical studies highlight durability, with >50% LDL-C reduction in non-human primates maintained for ~18 months after a single administration at a dose <1.0 mg/kg
• These data underscore potential of Scribe’s CRISPR-CasX-based epigenetic silencing platform, with a new preprint detailing the engineering behind the technology that offers an additional allosteric control layer designed to enhance precision and potency

Excerpt from the Press Release:

ALAMEDA, Calif.–(BUSINESS WIRE)–Scribe Therapeutics, Inc. (Scribe), a biotechnology company pioneering highly engineered CRISPR technologies designed to reshape the treatment of disease by enabling earlier intervention, improved outcomes, and longer, healthier lives, announced plans to enter the clinic in mid-2026 with STX-1150, its lead product candidate for the treatment of hypercholesterolemia, a major driver of atherosclerotic cardiovascular disease (ASCVD). STX-1150 is a novel liver-targeted therapy designed to epigenetically silence PCSK9 and durably reduce low-density lipoprotein cholesterol (LDL-C) without permanent DNA changes.

The announcement was revealed at the 44th Annual J.P. Morgan Healthcare Conference, underscoring Scribe’s mission to shift cardiovascular care from late, symptom-driven intervention to earlier, durable risk reduction grounded in human genetics.

Click the button below to read the entire Press Release:

Continue Reading The Press Release